Wedbush downgraded Keros Therapeutics (KROS) to Neutral from Outperform with a price target of $15, down from $47. The firm has removed ...

Dan Ives, Wedbush Securities global head of tech research, joins CNBC's 'The Exchange' to discuss the looming TikTok ban in ...

Fintel reports that on January 17, 2025, Wedbush downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from ...

ByteDance, TikTok’s parent company, is required to sell the app to a U.S.-based buyer or face a nationwide ban.

Investment analysts at Wedbush reduced their FY2025 earnings per share estimates for shares of KB Home in a note issued to ...

TikTok faces a ban in the U.S. as Chinese parent ByteDance struggles to divest the app, sparking uncertainty and a scramble ...

Wedbush currently has a “Outperform” rating and a $34.00 target price on the stock. The consensus estimate for Kiniksa Pharmaceuticals’ current full-year earnings is ($0.55) per share.

Wedbush analyst explains why Tencent is a suitable buyer of Ubisoft. He also expects Saudi Arabia's Savvy Games Group to bid ...

Netflix is set to report fourth-quarter results after the closing bell on Tuesday, with Wall Street analysts holding mostly ...

The popular platform could be banned on Jan. 19 under a federal law, while many parties have expressed interest in buying the ...

Tesla ( TSLA) stock jumped 3% Friday amid speculation that CEO Elon Musk could potentially buy TikTok. The social media ...